Table 3.
Covariates included in the analysis (mean ± SD, range).
| Variable | Lorazepam Learning group (n = 28) | Lorazepam Evaluation group (n = 31) | Midazolam Learning group (n = 21) | Midazolam Evaluation group (n = 33) |
|---|---|---|---|---|
| PEEP (mmHg) | 5.3 ± 2.5 (0–17) | 4.6 ± 2.5 (0–14) | 6.2 ± 2.5 (0–20) | 5.6 ± 3.3 (0–20) |
| Creatinine (µmol l−1) | 144 ± 119 (40–727) | 192 ± 157 (47–795) | 136 ± 85 (41–445) | 207 ± 262 (44–1197) |
| Urea (mmol l−1) | 14.6 ± 12.2 (3.2–59.7) | 20.4 ± 15.7 (4–120.2) | 15.8 ± 10 (1.8–58.5) | 17.5 ± 11.5 (2.8–55.2) |
| Albumin (g l−1) | 18 ± 6 (5–36) | 21 ± 5 (11–34) | 15 ± 5 (5–29) | 20 ± 4 (12–28) |
| CK (U l−1 30 °C) | 428 ± 2204 (5–19730) | 236 ± 438 (6–2636) | 1602 ± 5235 (3–19730) | 1017 ± 2061 (10–11420) |
| ASAT (U l−1 30 °C) | 50 ± 180 (2–2560) | 27 ± 47 (3–511) | 192 ± 142 (2–910) | 105 ± 173 (6–997) |
| ALAT (U l−1 30 °C) | 38 ± 51 (4–594) | 30 ± 35 (4–289) | 64 ± 79 (3–638) | 72 ± 103 (9–743) |
| AF (U l−1 30 °C) | 100 ± 67 (24–347) | 98 ± 70 (20–462) | 112 ± 73 (22–371) | 101 ± 122 (7–449) |
| Gamma-GT (U l−1 30 °C) | 85 ± 90 (4–442) | 71 ± 99 (5–435) | 98 ± 96 (4–442) | 74 ± 51 (2–214) |
| Bilirubin (µmol l−1) | 36 ± 65 (4–445) | 52 ± 122 (4–773) | 34 ± 38 (4–225) | 57 ± 115 (6–660) |
| Bilirubin glucuronide (%) | 0.64 ± 0.24 (0.17–0.94) | 0.69 ± 0.21 (0.21–0.93) | 0.7 ± 0.17 (0.17–0.89) | 0.7 ± 0.18 (0.21–0.89) |